Drip Infusion 100 How to obtain the approval of new indication for treatment of Behcets disease with refractory uveoretinitis
For the extension of the indication of treatment of diseases: Tanabe Seiyaku Co., Ltd. has received regulatory approval for anti-tumor necrosis factor (TNF), a monoclonal antibody infliximab preparation (R) for Drip Infusion 100 (infliximab generic name) was complicated with refractory uveoretinitis of Behcet who do not respond to conventional therapy, for the first time in the world. Behcets disease is a systemic inflammatory disease characterized by repeated episodes of relapses and recoveries refracatory, identified as oral ulcer on the mucous membrane, dermatitis, uveoretinitis, and the ulcer on the vulva.Sometimes the symptoms associated with inflammatory bowel, nerves and vessels. As vision loss due to repeated ocular attacks is the quality of life (quality of life) in
danger, and the suppression of the frequency of ocular attacks is especially important in therapy.And well known from recent research that TNF-a, proinflammatory cytokines, is deeply involved in the attacks in the eyes uveoretinitis. REMICADE (R) produces a dramatic therapeutic involved in inflammatory diseases of TNF binding to TNF-a and inhibiting its action, and is expected to be very effective in uveoretinitis. As a result of the test, there is evidence that administration of REMICADE (R) in patients with refractory Behcet uveoretinits suppressed the frequency of ocular attacks.
Bechets disease developed a lot in Japan, and throughout the country, around 17,000 people suffer from this disease. Tanabe Seiyaku to improve the quality of life of patients through the
proper use of REMICADE (R) by conducting post-marketing surveillance in all patients and provide reliable security, as we have been successfully used in rheumatoid arthritis and Crohns disease. On Tanabe Seiyaku Co., Ltd. Tanabe Seiyaku Co., Ltd. (TSE: 4508) is a manufacturer and distributor of pharmaceutical products for the cardiovascular system, circulatory system, central nervous system, respiratory and gastro-intestinal Pages: [1] 2